The unique short region of the varicella-zoster virus (VZV) genome contains two open reading frames which encode glycoproteins designated gpl and gplV (herpes simplex virus homologs gE and gI, respectively). Like its herpesviral counterpart gE, the VZV gpI gene product functions as a cell surface receptor (V. Litwin, W. Jackson, and C. Grose, J. Virol. 66:3643-3651, 1992 When gpl and gpIV were coexpressed in the same cell, the two glycoproteins were complexed to each other, as both proteins could be immunoprecipitated by antibodies against either gpl or gpIV. Coprecipitation did not occur as a result of a shared epitope, because gpl expressed alone was not precipitated by antibody to gpIV, and gpIV expressed alone was not precipitated by antibody to gpI. Pulse-chase analysis demonstrated that the gpI-gpIV association occurred early in processing; furthermore, this complex formation interfered with posttranslational modifications and thereby reduced the Mrs of the mature forms of both gpI and gpIV.
individually cloned into a pTM1 vector under control of the T7 promoter. Transfection of the cloned gpI or gpWV construct into HeLa cells previously infected with vaccinia recombinant virus expressing bacteriophage T7 polymerase resulted in a much higher level expression of each VZV glycoprotein than previously achieved. Synthesis of both gpl and gplV included intermediary partially glycosylated forms and mature N-and 0-linked final product. Transfections in the presence of 32Pi demonstrated that the mature forms of both gI and gpIV were phosphorylated, while similar experiments with [35S]sulfate showed that only the mature gpl was sulfated. When gpl and gpIV were coexpressed in the same cell, the two glycoproteins were complexed to each other, as both proteins could be immunoprecipitated by antibodies against either gpl or gpIV. Coprecipitation did not occur as a result of a shared epitope, because gpl expressed alone was not precipitated by antibody to gpIV, and gpIV expressed alone was not precipitated by antibody to gpI. Pulse-chase analysis demonstrated that the gpI-gpIV association occurred early in processing; furthermore, this complex formation interfered with posttranslational modifications and thereby reduced the Mrs of the mature forms of both gpI and gpIV.
Similarly, the molecular masses of the cotransfected gene products corresponded with those of the infected cell glycoproteins, a result which suggested that authentic gpI and gpIV were ordinarily found within a complex. Thus, the adjacent open reading frames 67 and 68 code for two glycoproteins which in turn form a distinctive sulfated and phosphorylated cell surface complex with receptor properties.
Varicella-zoster virus (VZV), one of the human alphaherpesviruses, is the etiological agent of two clinically distinct syndromes: (i) chicken pox (varicella) and (ii) shingles (herpes zoster). The genome of VZV, the smallest of the human herpesviruses, is 80 MDa and potentially contains approximately 70 open reading frames, five of which code for glycoproteins (5) . The VZV glycoproteins have been designated gpI, gpII, gpIII, gpIV, and gpV and have various degrees of amino acid homology to herpes simplex virus (HSV) glycoproteins gE, gB, gH, gI, and gC, respectively (5, 14) . Of the five VZV glycoproteins, gpI is the predominant virion envelope glycoprotein and also the major glycosylated VZV cell surface antigen. This type 1 integral membrane glycoprotein is known to undergo extensive co-and posttranslational modifications, including both N-linked and 0-linked glycosylation, phosphorylation, and acylation (8, 9, (14) (15) (16) 27) . Characterization of gpIV, the smallest of the five VZV glycoproteins, has been far less complete because the glycoprotein has been difficult to isolate from infected cultured cells (6) .
The gpI and gpIV glycoproteins are encoded by VZV genes 68 and 67, respectively, which are located within the unique short (Us) region of the VZV genome (5) . Their HSV homologs, gE and gI, are much less prominent species, yet they function as a receptor for the Fc portion of immuno-* Corresponding author. globulin G (IgG) (33) . Similarly, VZV gpl can behave as an Fc receptor for nonimmune IgG but much less efficiently than HSV gE (21) . HSV gI appears to increase IgG binding to gE but does not bind immunoglobulin directly; likewise, IgG does not attach to VZV gpIV (20, 21) . There has been considerable speculation about the relationship between the two Us glycoproteins of HSV or VZV described above.
HSV gE and gI are often coprecipitated (19, 20) ; likewise, numerous monoclonal antibodies which immunoprecipitate both VZV gpl and gpIV have been produced (9, 12, 25, 27) . In addition, one monoclonal antibody which precipitated the primary translation products of both gpI and gpIV in VZVinfected cells has been reported (36) . On the basis of computer-assisted sequence analysis, which found small similar fragments within gpI and gpIV, investigators proposed that the homologous regions harbor an epitope shared by VZV gpI and gpIV (35, 36) , but earlier evidence was inconsistent with this result: (i) when the sodium dodecyl sulfate (SDS) concentration in an immunoprecipitate was increased from 0.1 to 0.5%, the gpI specific antibodies no longer coprecipitated gpIV, and (ii) antibodies to gpI precipitated but failed to immunoblot gpIV (12, 25) . Rather than a shared epitope, these results suggested that gpl and gpIV associated with each other by protein-protein interactions during their biosynthesis. However, no kinetic studies have To address the issues mentioned above, we have subcloned VZV genes 67 and 68 into the pTM1 vector under control of the T7 promoter (26) . Transfection of the VZV gpI or gpIV construct into HeLa cells led to a much higher level of expression than was found in either VZV-infected cultured cells or any other transfection system tested previously by this laboratory (21) . Therefore, we have been able to investigate in greater detail than was previously possible the processing and posttranslational modifications of each glycoprotein, the formation of a gpI-gpIV glycoprotein complex within the rough endoplasmic reticulum-Golgi apparatus, and the antigenicities of the individual and complexed glycoproteins of this cell surface viral receptor. Altogether, this study further illustrates that the two VZV Us glycoproteins display several properties which distinguish them from the three major VZV unique long glycoproteins.
MATERLALS AND METHODS Construction of plasmids. The plasmid pTM1 was obtained from B. Moss, National Institutes of Health, Bethesda, Md. (26) , and the VZV genomic library was obtained from R.
Hyman, Palo Alto, Calif. The strategy for construction of the pTM1-gpl and pTM1-gpIV recombinant plasmids is shown in Fig. 1 . The genes encoding glycoproteins gpI and gpIV are located within the C fragment of the HindIII library, which has been cloned into the pBR322 vector (7) . The regions encoding full-length gpI and gpIV were amplified by polymerase chain reaction (PCR) using the pBR322-HindIII C plasmid as template DNA. The template DNA was subjected to 10 cycles of PCR amplification with the 5' oligonucleotide primer 5 Analysis of glycoproteins. Oligosaccharide structure of each viral glycoprotein was investigated with the following enzymes: endoglycosidase H (endo H), endo F, neuraminidase (sialidase), and endo-a-N-acetylgalactosaminidase (0-glycanase). The method for digestion with each enzyme has been previously described (24, 25, 29, 34) . In addition to studies using the enzymes listed above, studies were carried out with tunicamycin, which inhibits the addition of N-linked oligosaccharides to glycoproteins. Reagents were purchased from Sigma and Genzyme.
RESULTS
Expression of gpl and gpIV in transfected HeLa cells and their reactivities to monoclonal antibodies. HeLa cells were infected with recombinant vaccinia virus expressing the bacteriophage T7 RNA polymerase and then transfected by lipofection with pTM1-gpI, pTM1-gpIV, or pTM1 vector only. At 14 h posttransfection, cells were analyzed for synthesis and intracellular localization of the VZV gene products. The probe for gpl was monoclonal antibody 3B3, which recognizes an as-yet-undefined determinant in the N terminus of VZV gpI (25) . The probe for VZV gpIV was monoclonal antibody 6B5, which also recognizes an undefined antigenic site located within the N terminus of this type 1 glycoprotein (22) . Expression of gpl and gpIV was easily detectable in the cytoplasms of the acetone-fixed transfected cells ( Fig. 2A and E) . whether monoclonal antibody 3B3 or 6B5 cross-reacted with individually expressed viral glycoproteins, we stained the gpI-transfected cells with antibody 6B5 and the gpIV-transfected cells with antibody 3B3. As shown in Fig. 3 , antibody 3B3 reacted specifically with fixed and unfixed gpl-transfected cells. Similarly, antibody 6B5 specifically bound to gpIV-transfected cells. From this experiment, it was concluded that neither monoclonal antibody detected an epitope shared between glycoproteins gpI and gpIV. Even though antibody 3B3 precipitates both gpl and gpIV in the presence of a low concentration of SDS, it obviously recognized an epitope confined to gpI. This experiment further confirmed the specificity of antibody 6B5, which was first tested against VZV-infected cells as part of a flow cytometric analysis of viral glycoproteins detectable on the cell surface (22) .
Specificities of other anti-gpl and -gpIV monoclonal antibodies. Because of the reports of a shared epitope between gpl and gpIV (35, 36) , several additional monoclonal antibodies which precipitated either gpI or gpIV or both gpI and gpIV were tested by immunofluorescence analyses. In these studies, the pTM1-gpI and pTM1-gpIV transfectants were the cell substrates, onto which were added dilutions of each monoclonal antibody. As shown in Table 1 , we evaluated 19 monoclonal antibodies produced by several different fusions in two separate institutions. Some of these antibodies, e.g., 6G9, precipitate almost equal amounts of each glycoprotein in VZV-infected cells (12) . In every case, each monoclonal antibody reacted by indirect immunofluorescence assay with only one transfected cell culture; viz., no antibody demonstrated cross-reactivity with both gpI and gpIV, even though the same antibody may have precipitated both glycoproteins under typical conditions of immunoprecipitation with VZVinfected cell antigen. No tested antibody was excluded from Table 1 because of ambiguous findings. Because of these results, all further studies were carried out with the two antibodies 3B3 (anti-gpI) and 6B5 (anti-gpIV).
Analysis of glycosylation of gpl. VZV gpl has been isolated from infected cells and subjected to extensive biochemical analysis (25) . To ensure that gpI synthesized under the vaccinia virus-T7 RNA polymerase transfection conditions resembled authentic gpI, the individual product was similarly investigated. To this end, HeLa cells were transfected with pTM1-gpI for 4 h, and then the cells were labeled with 100 ,uCi of [ S]methionine for 2 h. HeLa cells transfected with pTMl vector alone served as a control. Lysates of transfected cells prepared as described in Materials and Methods were immunoprecipitated with monoclonal antibody 3B3 and analyzed by SDS-polyacrylamide gel electrophoresis (PAGE). The results in Fig. 4A show both an 81-and a 100-kDa species in pTM1-gpI-transfected cells (lane 2) but not in pTM1-transfected cells (lane 1). The two proteins corresponded to previously described partially and fully glycosylated gpI forms in VZV-infected cells (25, 27) . In the presence of tunicamycin, which inhibits the addition of N-linked but not 0-linked oligosaccharides to the native protein, two proteins of approximately 73 and 88 kDa were detected, a result which suggested that the 73-kDa form was the nonglycosylated backbone of gpI, while the 88-kDa form was an 0-linked product (lane 3).
To study glycosylation in more detail, endoglycosidase digestions were performed. Figure 4A shows the digestion of immunoprecipitates with endo H, an enzyme which predominantly cleaves between the two proximal N-acetylglycosamine residues of high-mannose oligosaccharides but does not affect complex oligosaccharides (29, 34) . Radiolabeled gpl immunoprecipitates were incubated in the presence of either endo H or an equivalent amount of water, and then the proteins were precipitated with cold acetone and subjected to electrophoretic separation. As described above, antibody 3B3 precipitated two gpI species (gplOO and gp8l) (Fig. 4A, lane 4) . Endo H treatment reduced the Mr of gp8l to 73 kDa, whereas the relative migration of gplOO was unchanged (Fig. 4A, lane 5) . This result indicated that gp8l contained high-mannose oligosaccharides, while the oligosaccharides on gplOO were already fully processed to complex moieties (endo H resistant). To determine whether gpI contained 0-linked oligosaccharides, the cell lysates from gpI-transfected cells were subjected to serial neuraminidase and O-glycanase digestions. As shown in .. cells contained 0-linked glycans. This analysis also confirmed the similarity in biosynthesis of gpI in transfected cells and VZV-infected cells (25) .
Analysis of glycosylation of gplV. Only limited biochemical studies of the gpIV glycoprotein have been carried out, because gpIV is present in infected cells in relatively small quantities (6, 14) . Likewise, only a small percentage of cells was seropositive in a transfection system previously described by this laboratory (21) . Because of these problems, we subcloned the gpIV gene into pTMl vector and reexamined expression of gpIV. For these purposes, HeLa cells transfected with pTM1-gpIV were radiolabeled, solubilized, and subjected to immunoprecipitation studies with monoclonal antibody 6B5. As shown in Fig. 4B , prominent 50-and 64-kDa species were detected in pTM1-gpIV-transfected cells but not in cells transfected with pTM1 vector only (lanes 1 and 2) . In the presence of tunicamycin, the 64-kDa species disappeared, while two proteins of approximately 36 and 45 kDa were detected (lane 3), a result which suggested that the gpIV backbone (36 kDa) may be further processed by 0-linked glycosylation (45 kDa). The mature 64-kDa protein was resistant to endo H digestion, presumably because it contained fully processed N-linked glycans (as well as 0-linked glycans), while an intermediary 50-kDa protein was sensitive, a result which indicated that it contained high-mannose glycans (Fig. 4B, lanes 4 and 5) .
To confirm that gpIV contained 0-linked oligosaccharides, the cell lysates from gpIV-transfected cells were subjected to neuraminidase and O-glycanase digestions. As shown in Fig. 4B , removal of N-acetylneuraminic acid residues from the 64-kDa protein generated a protein with a molecular mass of 57 kDa (lane 7 5) .
Complex formation by gpI and gpIV. As mentioned above, the relationship of the two glycoproteins gpI and gpIV has not yet been resolved. Because of the high expression of gpIV in the vaccinia virus-pTM1 system, we were able for the first time to investigate the fates of the individual gene products. To determine whether gpI and gpIV formed a complex when both proteins were expressed together, we singly and dually transfected with pTM1-gpI and pTM1-gpIV. HeLa cells expressing gpI, gpIV, or gpI and gpIV were metabolically labeled with [3 S]methionine for 2 h. Transfected cell cultures were detergent solubilized, and the lysates were immunoprecipitated with antibodies to gpI or gpIV. The results in Fig. 5 showed that gpI and gpIV were expressed and specifically precipitated by their respective antibodies (lanes 3 and 7). Anti-gpIV monoclonal antibody 6B5 did not immunoprecipitate gpI from cell extract transfected with gpl alone (lane 2), nor did anti-gpl monoclonal antibody 3B3 immunoprecipitate gpIV from cells transfected with gpIV alone (lane 6). In cells cotransfected with DNAs encoding gpI and gpIV, both proteins were expressed and both were precipitated by antibody to either gpI or gpIV (lanes 4 and 8). The results were the same, regardless of whether SDS-PAGE was performed under reducing or nonreducing conditions (former gel not shown). On the basis of the immunoprecipitation data given above, we concluded that gpI and gpIV formed complexes when coexpressed in the same cells. Kinetics of VZV glycoprotein complex formation. The ability to detect an interaction between gpI and gpIV by metabolic labeling in HeLa cells also permitted the study of the rate and site of complex formation in the cell. Transfected cells expressing both gpI and gpIV were pulsed labeled with [35S]methionine for 15 min and then either lysed immediately or incubated in chase medium containing unlabeled methionine for 10, 30, 60, and 90 min prior to lysis. Immunoprecipitates formed with both antibodies were then analyzed by SDS-PAGE to assess coprecipitation of gpl and gpIV. The results in Fig. 6 indicated that the association of newly synthesized gpI and gpIV was detectable during the 15-min pulse period (lanes 1 and 2) . This result suggested that complex formation occurred as an early processing event, probably in the endoplasmic reticulum (31 coprecipitated with gpI during the pulse period (lane 2) and 35% coprecipitated after 90 min of chase (lane 10). An alternative explanation for the apparently rapid association between gpI and gpIV was that the event occurred during the preparation of the cell lysate and not during actual biosynthesis of the glycoproteins in the transfected cell. To examine this possibility, we attempted to reconstitute the interaction by expressing the proteins separately and mixing the solubilized cell lysates. Even after prolonged incubation of the two cell lysates, we were not able to detect gpI-gpIV complex formation (data not shown). This result indicated that gpI-gpIV complex formation was not an artifact of detergent lysis.
Effect of complex formation on processing of gpl and gpIV. The association of VZV gpI and gpIV during the 15-min pulse indicated that the event occurred early in the exocytic pathway. Furthermore, a reexamination of Fig. 5 suggested that the Mr of either gpI or gpIV was reduced during a cotransfection compared with a single transfection (compare lanes 3 and 4 with lanes 7 and 8). To confirm this observation, the experiment was repeated under conditions of SDS-PAGE designed to further separate the individual constituents of gpI. As seen in Fig. 7 , the Mr of the mature gpI was 100 kDa when cells were transfected with gpI gene alone (lane 1), while the Mr shifted to 98 kDa as a result of cotransfection with gpIV gene (lane 2). The Mr of a previously described 81-kDa high-mannose form of gpI was not changed, regardless of whether gpI was transfected alone or with the gpIV gene. In earlier reports from this laboratory, the Mr of gpl from an infected cell culture was estimated to be 98 kDa (25) . To verify that the mass of gpI from an infected culture resembled that from a cotransfection, gpI was isolated under three conditions: (i) from infected cells, (ii) from cotransfected cells, and (iii) from cells transfected with gpI gene alone. As shown in Fig. 7 , the Mr of gpl from infected cells was similar to that of gpI from cotransfected cells (lanes 4 and 5), while gpI from singly transfected cells had a higher Mr (lane 3). Similarly, the data for gpIV were compared in the three circumstances listed above. Again, the singly transfected culture had a more heterogeneous gpIV product (lane 8) with a higher Mr, while gpIV recovered from either infected cells or a gpI-gpIV-cotransfected culture had a lower Mr (Fig. 7, lanes 6 and 7) .
We considered the possibility that the differences in Mr were related to the switch in cell substrates, i.e., human melanoma cells for infection and HeLa cells for infectiontransfection. To this end, we repeated the infection-transfection experiments in human melanoma cells. Although transfection was not as efficient as in HeLa cells, the results were similar to those described above; i.e., the singly transfected glycoprotein had a higher Mr than the glycoprotein from a cotransfected culture (data not shown). The most reasonable explanation for these events is an alteration in glycosylation, in particular, because gpI-gpIV complex formation precedes the posttranslational modifications which occur in the Golgi apparatus. In an attempt to define differences in N-and 0-linked glycoproteins before and after complex formation, the gpI-gpIV complex was subjected to analysis with endo F, neuraminidase, andO-glycanase, but no marked changes in sensitivity were noted. However, a comparative analysis of complexed versus noncomplexed glycoproteins was complicated by the fact that both gpI and gpIV have three or more potential N-linked sites and perhaps as many 0-linked sites. If gpl-gpIV complex formation impaired oligosaccharide processing of only one chain, an event which could lower the Mr by 2,000, we would have difficulty detecting this alteration by the methods described above.
Sulfation of VZV gpI and gpIV. In the sections above, we demonstrated that the Mr of the each complexed glycoprotein was reduced compared with the Mr of the individually transfected VZV glycoprotein. The Mr of a glycoprotein can be greatly altered by two late posttranslational modifications: sialation and sulfation. Prior data in Fig. 7 suggested that complex formation interferes with processing of the mature forms and thereby may decrease sialation. To determine whether oligosaccharide sulfation was also involved with the mobility changes, we investigated whether this posttranslational modification was seen in the individually transfected VZV gene products and, if so, whether this modification was altered under conditions of cotransfection with the two glycoprotein genes. To this end, we added 3"So4 to culture medium overlying VZV pTM1-gpI-or pTM1-gpIV-transfected cells and analyzed the cell lysates by immunoprecipitation. As shown in Fig. 8 , there were no sulfated proteins precipitated from cells transfected with pTM1 vector only (lane 1), nor was any sulfated protein detected in precipitates of the pTM1-gpIV-transfected cell (lane 2). In pTM1-gpI-transfected cells, however, the mature VZV gpI form was highly sulfated (lane 3). Cotransfection of gpI and gpIV did not abolish sulfation of gpl (lane 4). Figure  8 again illustrated the effect of this protein-protein association in lowering the Mr of VZV gpl.
Phosphorylation of VZV gpl and gpIV. The VZV gpl product is characterized by phosphorylation of its polypeptide backbone both in cell culture and in vitro by cellular kinases (15) . The precursor form of gpIV in VZV-infected cells was also shown to be phosphorylated during in vivo labeling (36) . Yet, investigations to further define gpIV phosphorylation have been inhibited by the small yields of this glycoprotein within either the infected cell or the transfected cell. Furthermore, we questioned whether phosphorylation of the viral glycoproteins was altered by gpl-gpIV complex formation. Because of the high expression of gpl Reduction in gpI-gpIV complex formation. To further analyze gpI-gpIV complex formation, we produced a gpI mutant with a deletion in a highly conserved region of gpI (21, 28) .
On the basis of the VZV DNA sequence published by Davison and Scott (5) , two NdeI restriction sites were localized in the exocytoplasmic portion of gpI. After excision of the intervening nucleotides from the pTM1-gpl construct, a truncated form of gpI with a deletion of 105 amino acid residues (amino acid residues 342 to 446) was constructed (Fig. 10A ). This deletion mutant lacked 6 cysteine residues from a total of 10 cysteines in the ectodomain of gpl. When HeLa cells were transfected with the mutant construct, an immunofluorescence study showed that the gene product could be detected on the surfaces of living cells (Fig. 10B) ; this result indicated not only that the truncated glycoprotein was processed in the Golgi complex and transported to the outer cell membrane but also that the epitope for monoclonal antibody 3B3 was located toward the N terminus of gpl. Dual transfections were performed with both pTM1-gpIV and the truncated gpI gene. As illustrated in Fig. 10C , analysis of the gene products by immunoprecipitation with antibodies to gpI and gpIV found that wild-type gpl was capable of binding to gpIV (lanes 3 and 4) while truncated gpI showed a reduction in the degree of coprecipitation (lanes 1 and 2). It is likely that the six cysteines will be involved in intramolecular disulfide bond formation, a process which occurs in the endoplasmic reticulum, the site of gpI-gpIV complex formation (Fig. 6 ). Thus, a substantial deletion of cysteine residues could alter the conformation of the gpI molecule and thereby impair its protein-protein interaction with gpIV in the endoplasmic reticulum.
DISCUSSION
The relationship of the two VZV glycoproteins gpl and gpIV has been a subject of speculation since the initial observations that they were frequently coprecipitated by murine monoclonal antibodies. In this paper, we readdressed this issue in a multistep process. First, an improved transfection system was required. In an earlier study, transfection had been carried out by a more-traditional method (21) (4, 18) and p56Ck tyrosine kinase (30) .
Under conditions of transfection within the vaccinia virus-T7 RNA polymerase system, the yields of the two VZV glycoprotein gene products were estimated to be as much as 10-fold greater than previously achieved by transient transfection. This approach appeared to be superior to having recombinant vaccinia virus themselves express herpesviral glycoprotein genes (1) in that we were able to mimic or exceed the gpI glycoprotein levels found in VZV-infected cells. Indeed, for VZV gpIV, the levels were much higher as gauged by degree of immunostaining and lengths of exposure of fluorograms: 1 day for infection-transfection versus up to 4 months for infection (6) . Thus, we have been able to perform studies of gpI-gpIV interactions not possible under previously described conditions of transfection or infection of cultured cells. The stoichiometry of the gpl-gpIV complex remains to be resolved. Based on the data presented here as well as on prior results with infected cells (6, 8, 25, 27) , a plausible explanation is that the complex in infected cells consists of more molecules of gpl than of gpIV.
In (35) .
Our phosphorylation experiments demonstrated that both intermediary and mature forms of gpIV were phosphorylated in vivo. An earlier report suggested that only the precursor forms of gpIV were phosphorylated in VZV-infected cells (36) . An explanation for this discrepancy is the low level of gpIV expression in virus-infected cells. Other interesting aspects of gpIV phosphorylation were apparent in the transfection system; for example, the mature form of gpIV appeared more highly phosphorylated during cotransfection than when singly transfected. Thus, complex formation may make a phosphorylation site more accessible to the protein kinase, or alternatively, highly phosphorylated gpIV is better able to form protein-protein complexes with gpl. To further investigate this issue, we have devised a protocol by which to mutagenize the putative phosphorylation sites in the cytoplasmic tails of the glycoproteins (37) . Further progress has awaited completion of the improved transfection system described in this report.
In addition to phosphorylation, the property of oligosaccharide sulfation was also addressed with VZV gpI and gpIV. A major sulfated HSV glycoprotein is gE (VZV gpI homolog) (17) . In this study, we found that VZV gpI was heavily sulfated, while gpIV was not. The fact that there must be specificity to oligosaccharide sulfation is indicated by similarities between HSV and VZV homologs. While gpl is the (32) .
b SwissProt accession numbers are P09258 for VZV gpIV and P06487 for HSV gI. GenBank and EMBL accession numbers are M14336 for PRV gp63 and M36299 for equine herpesvirus (EHV) gI.
I Ratio is equal to the quality score divided by the number of residues in the shorter of the two compared segments.
predominant VZV glycoprotein synthesized in infected cells, gE is a relatively obscure HSV glycoprotein, yet both are heavily sulfated. We have examined the amino acid sequence of gpI for the tripeptide recognition marker ProXaaArg/Lys utilized by GaINAc-transferase when the trimer is located six to nine residues amino terminal to an N-linked glycosylation site (11), but we did not find it. Therefore, oligosaccharide sulfation of gpI does not appear to be similar to the process recently described for the sulfated glycoprotein lutropin.
Finally, we performed a computer-assisted sequence analysis of VZV gpIV and its alphaherpesviral homologous glycoproteins. In previous reports (21, 28) , we and others showed that VZV gpI closely resembled pseudorabies virus (PRV) gpl and HSV gE not only in the exoplasmic portions but also in the cytoplasmic portions of the respective molecules. In Table 2 , we compare VZV gpIV with HSV gI, PRV gp63, and gI of equine herpesvirus 1, a third alphaherpesvirus. The sequence identity reached as high as 39% in one domain; i.e., an extracellular region of VZV gpIV between amino acids 50 and 150 contains three cysteine residues which were highly conserved across the four viruses. These results closely resemble those previously described for VZV gpI and its homologs; viz., the regions of highest homology were the cysteine-rich portions of the exoplasmic molecule (21, 28) . Presumably, intramolecular disulfide binding contributes to the tertiary structure of each of the two glycoproteins and this native conformation facilitates intermolecular complex formation. Since the homology extends through the lengthy cytoplasmic portions of the two alphaherpesviral glycoproteins, the Fc receptor complex probably has similar functions in each virus. Recent investigations of the PRV counterparts indicate that the viral glycoproteins behave as adhesion molecules and provide specificity for attachment to neuronal cells (2, 3, 23 
